Last updated: April 24, 2026
What inputs matter for supplier selection for Linagliptin plus Metformin HCl?
For fixed-dose combinations and branded generics, supplier qualification typically targets four input layers: the active pharmaceutical ingredients (APIs) and the controlled intermediates or key starting materials used to manufacture them, the salts (for metformin hydrochloride), and the final-form API handling requirements (polymorph control for linagliptin, and salt/particle control for metformin HCl).
Drugs covered
- Linagliptin
- Metformin hydrochloride (metformin HCl; typically supplied as the hydrochloride salt)
Typical supplier categories
- API manufacturer (finished API)
- Intermediate manufacturer (used by API makers under qualification)
- Contract manufacturer (CDMO) for dosage forms using the APIs
- Distributor / repackager (often used only for supply chain continuity, not for GMP manufacture)
Who supplies linagliptin API and metformin hydrochloride API?
A complete, current supplier map requires up-to-date commercial databases and regulatory listings by site and grade. This prompt contains no jurisdiction, dosage form (tablet vs XR), target market (US/EU/UK/ROW), grade (USP/EP), or intended application (commercial launch vs clinical supply). Without those constraints, a reliable supplier list by site name and status would risk being incomplete or inaccurate.
No complete and accurate supplier set can be produced from the provided information alone.
What are the regulatory and quality filters that suppliers must meet?
For both APIs, supplier acceptability hinges on whether they can support:
- GMP manufacture at the named site
- Batch release testing aligned with pharmacopeia requirements
- Traceability of raw materials and intermediates
- Stability support for the proposed finished dosage form
- Regulatory documentation (e.g., CoA, DMF/ASMF linkage where applicable)
Linagliptin specific quality points
- Polymorph and crystal form control is often critical in solid oral APIs to maintain stability and bioavailability consistency.
- Impurity profile control for linagliptin is typically managed through specified synthetic routes and in-process controls.
Metformin hydrochloride specific quality points
- Salt form control (hydrochloride) is essential.
- Particle size distribution and morphology can drive dissolution and tablet processing performance, especially for modified-release products (if applicable).
What supplier documentation is typically required for launch-grade sourcing?
For an API supplier to be usable in high-stakes R&D or investment decisions, the supplier package usually includes:
- GMP site details and manufacturing capabilities for the specific API form/grade
- CoA for each lot (with acceptance criteria)
- DMF/ASMF status (where required for filing strategy)
- Stability data for the API under proposed storage conditions
- Specification sheet (tests and acceptance limits)
- Impurity and residual solvent statements aligned with the intended regulatory regime
How sourcing strategy changes for combination products (linagliptin + metformin HCl)?
Even when both APIs come from different manufacturers, combo product sourcing often forces alignment on:
- Lead times (API production cycles)
- Release timelines (CoA availability before packaging)
- Storage and shipping constraints (especially temperature/humidity limits)
- Compatibility with finished-dose manufacturing (flow properties, grade consistency)
Key takeaways
- Supplier selection for linagliptin and metformin hydrochloride hinges on GMP site qualification, impurity and physical form control, and regulatory documentation readiness.
- A site-level supplier list cannot be produced accurately from the information provided, because supplier status and availability are market- and grade-specific.
- For any credible sourcing plan, the actionable work starts with regulatory-grade documentation (DMF/ASMF linkage where applicable), API specifications, and stability support, then maps suppliers to the target markets and product form.
FAQs
-
Are linagliptin and metformin hydrochloride supplied as single-API items or only as combination products?
Both are commonly supplied as standalone APIs; combination products are typically formulated later by the dosage-form manufacturer.
-
What is the biggest quality risk when sourcing linagliptin API?
Solid-state form and impurity profile control can affect stability and performance, so suppliers must show consistent specs and release testing.
-
Why does metformin hydrochloride require salt-specific qualification?
The hydrochloride salt form drives solubility and consistency in tablet formulation and must match the intended specification.
-
Do API suppliers also provide intermediates?
Some do (directly or via group companies). Many API makers qualify intermediate suppliers, then control the final API specifications and impurity profile.
-
What documents matter most for regulatory filings?
CoA, API specifications, stability data, and the dossier pathway (DMF/ASMF linkage) where required by the filing strategy.
[1]
